Rigel Pharmaceuticals | RIGL - Equity Capital And Reserves


Rigel Pharmaceuticals reported $117.61M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -221.22M 49.89M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Celldex Therapeutics USD 456.23M 70.94M Mar/2026
Daiichi Sankyo JPY 1.71T 57.86B Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Veracyte USD 1.34B 34.83M Mar/2026